当勃起功能障碍治疗阻碍视力时:ST-BRVO在健康男性中服用西尔德纳菲尔后
Nilesh Giri1, Deepaswi Bhavsar1, Renu Magdum1
1Department of Ophthalmology, Dr. D Y Patil Medical College, Hospital and Research Centre, Pune, India.
用于治疗勃起功能障碍的西尔德纳菲尔,即使在健康人群中也很少引起视网膜静脉封闭 (RVO). 这一案例凸显了西尔德纳菲尔和视力威胁的血管事件之间的潜在联系.
科学领域:
- 眼科医生 眼科 眼科
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 西尔德纳菲尔 (一种PDE5抑制剂) 通常用于勃起功能障碍,并且通常耐受良好.
- 眼血管并发症,包括视网膜静脉封闭 (RVO),在使用西尔代纳菲尔时很少报告.
- 这些事件可以发生在没有典型的系统性风险因素的个体中.
研究的目的:
- 报告西尔代纳菲尔使用后枝状视网膜静脉封闭 (BRVO) 的情况.
- 在健康个体中调查西尔代纳菲尔和视网膜血管事件之间的潜在关联.
- 提高临床医生对这种罕见并发症的认识.
主要方法:
- 一个55岁的男性的病例介绍,他以前没有病史.
- 患者在一次100毫克的西尔代纳菲尔剂量后48小时出现了突然的视力模糊.
- 临床评估包括 fundus 检查,斑点的评估,以及全面的全身/血液检查;用静脉内贝瓦西祖马布治疗.
主要成果:
- 临床评估显示了一个超时分支RVO与黄斑胀.
- 系统和血液检查,包括血栓友病查和心脏评估,结果正常.
- 采用静脉内贝瓦西祖马布治疗导致了解剖学和视觉的改善.
结论:
- 西尔德纳菲尔的使用可能与视网膜血管事件 (如BRVO) 相关,即使在健康人群中也是如此.
- 时间关联和缺乏风险因素表明潜在的剂量独立的血管敏感性.
- 临床医生应该考虑西尔代纳菲尔作为RVO发展的潜在因素,即使没有传统的风险因素.
更多相关视频
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
